Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. junior Avg
|
New words:
AA, AAA, accessed, accessibility, accessible, activist, Adastra, adequacy, adware, AI, appeal, arguing, artificial, AUC, autonomy, bad, Barbara, BeiGene, Beijing, bilirubin, biometric, BIW, bloc, BMB, Brazilian, Bristol, broadening, Brukinsa, BTK, businesspeople, carbon, CCPA, ceiling, Centre, cessation, Chamber, Cmax, CMC, COBRA, Colorado, Commerce, Connecticut, Conviction, Cosmetic, CPRA, cracking, credential, crystal, cutoff, cybersecurity, deletion, departure, derogate, Diffuse, diffused, disaggregated, disaggregation, DLBCL, DLT, downgraded, driver, Durable, EEA, effector, element, email, emavusertib, energy, enitociclib, enitocliclib, erected, evidenced, excretion, exfiltration, exhausted, expiry, female, Fitch, Florida, forgotten, Francomano, gas, geared, GmbH, GMP, greatly, greenhouse, Hampshire, hardware, harvesting, Head, heading, hereto, hesitancy, hierarchical, House, humidity, hypokalemia, IFN, impartial, impracticable, inaugural, incorrect, Indiana, injured, intelligence, intercede, interoperable, interplay, intrusion, Iowa, leaked, legislature, legitimate, longest, lypmhoma, male, malware, marked, misuse, misused, monetize, Montana, MTD, multiplied, NIST, noteworthy, objectionable, ODD, opt, Oregon, PDAB, peak, perpetration, phishing, portal, procure, procuring, prominent, proportionally, proportionate, PTCL, quantitative, QW, recourse, regular, relocate, reluctance, remeasured, Republic, residing, resurgence, retaliated, retaliatory, Rezlidhia, Rigel, Robert, sanctioned, sea, sector, server, shaping, Shield, software, sovereign, spoilage, steadily, stricter, strictly, stuffing, supplier, Switzerland, tampered, Tennessee, text, theft, thereon, tract, UK, uncertainly, unfounded, unintentional, unlawfully, unwilling, upgrade, upper, Utah, Uyghur, Virginia, weather, weekly, Wood, wrongful, Xinjiang, zanubrutinib, zotiraciclib
Removed:
abstract, Abstral, accrue, afforded, AG, Alice, Amgen, amortization, amounting, Anderson, applicability, attack, batch, biomedical, blocker, BMS, cGCP, characteristic, clearance, CLS, comparability, comprise, constitutionality, CTL, culminate, Daiichi, decided, delisted, dense, devoted, discounted, dismissed, Dohme, duty, electrical, embedded, emerge, enactment, feature, fentanyl, fiduciary, fire, flow, formally, Foundation, gauge, Genentech, Gilead, grouped, Henry, HJF, IHC, immunohistochemistry, inadvertent, indefinite, infected, instructing, inventive, isolated, IST, Jackson, Johnson, legacy, lived, magrolimab, Mayo, memorandum, military, Myriad, negotiated, NPS, opioid, phenomena, PLC, prolongation, reciting, recoverable, reflected, released, repealed, Roche, RYDAPT, Sankyo, Servier, Sharp, sourced, Squib, staining, subjected, sum, Taxpayer, telecommunication, TIBSOVO, tier, transform, validated, Veterinary, vulnerability, welfare, widespread, XOSPATA
Financial report summary
?Competition
Pfizer • AMGEN • Celgene • Immunogen • Incyte • Gilead Sciences • Aptose Biosciences • Roche Holding • Astrazeneca • RocheManagement Discussion
- Further analysis of the changes and trends in our operating results are discussed below.
- There was no licensing revenue for the year ended December 31, 2023 and $1.0 million in licensing revenue for the year ended December 31, 2022 related to approval by China's National Medical Products Administration, or NMPA, of an Investigational New Drug, or IND, application filed by 3D Medicines for a small Phase 1 clinical trial investigating safety of GPS in China.
- There was no cost of licensing revenue recognized during the year ended December 31, 2023, and $0.1 million of sublicensing fees payable under our license from MSK in connection with the 3D Medicines Agreement during the year ended December 31, 2022.